Abstract:
The disposable eye patch further comprises a rim ember circumferentially attached to the second layer, wherein the rim member comprises an adhesive for sticking the eye patch to cover the human eye. The adhesive is a safe for contact with the human skin and can be easily removed and discarded after a single use. The disposable eye patch further comprises an absorbent layer attached to the first layer facing the outer surface of the eye.
Abstract:
A model-based method is described which defines a rigid transformation between two co-ordinate systems that reduces the accuracy requirements on the quality of the data-set (including, but not restricted to, the error in the acquisition process, and the number and spread of the points) measured in one of the two co-ordinate systems by identifying a set of remote correspondences that are used to bind the convergence process. The method can be used in minimal-access orthopaedic surgery to improve the accuracy of limb registration. Specific instances include femoral registration, by estimating the functional center of the hip joint in both co-ordinate systems to be co-registered, and tibial registration, using the ankle center as a distant set of paired correspondences. Accuracy can be measured in a variety of ways, including, but not restricted to, evaluating the mis-alignment between the two co-registered objects.
Abstract:
The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein n, Y, R1, R2, R3, and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions containing them and their use as pharmaceutical agents.
Abstract:
The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, R1, R2, R3, R4, R5 and R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.
Abstract:
The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein n, Y, R1, R2, R3, and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions containing them and their use as pharmaceuticals.
Abstract:
The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein X, Y, A, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as therapeutics.
Abstract:
The present invention relates to a structural health monitoring system, for example a system used in the non-destructive evaluation of an aircraft structure. The present invention provides a method and apparatus for evaluating one or more anomalies within a structure using a structural health monitoring system that includes at least three transducers arranged in operative contact with the structure such that no two transducers are aligned to be parallel. A transducer excites an elastic wave that propagates through the structure, and reflections from any anomalies within the structure are collected by the three transducers. These collected signals are analysed to identify an anomaly within the structure. Time of flight techniques are used to determine the location of the anomaly.
Abstract:
The present invention is concerned with novel pyridazinones of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used for the treatment of CNS disorders.
Abstract:
The present invention relates to compounds of the formula (I) wherein R1, R2, X and n are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use for the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.
Abstract:
The present invention relates to compounds of the general formula as dual modulators of the 5-HT2a and D3 receptors useful against CNS disorders, wherein A, R1, R2, n, p, q and r are as defined in the specification.